Frank G J, Knapp L E, McLain R W
Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan.
Angiology. 1989 Apr;40(4 Pt 2):405-15. doi: 10.1177/000331978904000410.
A comprehensive analysis of the reporting of adverse events, withdrawals due to adverse events, and serious adverse events has been conducted on 2,010 patients treated with quinapril hydrochloride. An analysis of all events (from both double-blind and open label studies combined) showed no increase in the incidence of events reported in congestive heart failure (CHF) patients compared to hypertensive patients. When the data for all studies were combined, an age analysis showed no increase in the total reporting of adverse events in the 379 elderly patients studied. The incidence of events was lower in those patients who did not take concomitant diuretic therapy. A comparison of the double-blind phases showed quinapril to have a lower incidence of adverse events than captopril, enalapril, or chlorthalidone. An analysis of the onset of events, or withdrawals, did not show an increase with time on quinapril therapy, and no dose-relationship. A review of serious adverse events did not reveal an unexpected occurrence or a high incidence of serious events considered to be related to quinapril therapy. The proportion of patients who experienced "first-dose" hypotension, or symptomatic hypotension was similar to captopril or enalapril. Quinapril, a nonsulfhydryl ACE inhibitor, has been extensively studied and is equally well tolerated in the young and elderly for the treatment of hypertension and CHF.
对2010例接受盐酸喹那普利治疗的患者的不良事件报告、因不良事件停药情况以及严重不良事件进行了全面分析。对所有事件（包括双盲研究和开放标签研究的数据合并）进行分析显示，与高血压患者相比，充血性心力衰竭（CHF）患者报告的事件发生率没有增加。当所有研究的数据合并后，年龄分析显示，在379例老年患者中，不良事件的总报告率没有增加。未同时接受利尿剂治疗的患者事件发生率较低。双盲阶段的比较显示，喹那普利的不良事件发生率低于卡托普利、依那普利或氯噻酮。对事件发生或停药的分析未显示随着喹那普利治疗时间的延长事件发生率增加，也未显示剂量关系。对严重不良事件的审查未发现与喹那普利治疗相关的意外事件发生或严重事件的高发生率。经历“首剂”低血压或症状性低血压的患者比例与卡托普利或依那普利相似。喹那普利是一种非巯基血管紧张素转换酶抑制剂，已得到广泛研究，在年轻人和老年人中治疗高血压和CHF时耐受性相当好。
